BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duvoux C, Roudot–thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard P, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux G, Chazouillères O, Salame E, Hilleret M, Lebray P, Abergel A, Debette–gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012;143:986-994.e3. [DOI: 10.1053/j.gastro.2012.05.052] [Cited by in Crossref: 438] [Cited by in F6Publishing: 374] [Article Influence: 48.7] [Reference Citation Analysis]
Number Citing Articles
1 Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:71-79. [PMID: 28553624 DOI: 10.2147/jhc.s105777] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
2 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 16.0] [Reference Citation Analysis]
3 Huang LF, Wan P, Xu DW, Jeong S, Feng MX, Zhang JJ, Xia Q. Nomogram predicting pulmonary metastasis of hepatocellular carcinoma after liver transplantation. Oncotarget 2018;9:2425-34. [PMID: 29416782 DOI: 10.18632/oncotarget.23418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Andreou A, Gül S, Pascher A, Schöning W, Al-Abadi H, Bahra M, Klein F, Denecke T, Strücker B, Puhl G. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma. HPB (Oxford). 2015;17:168-175. [PMID: 25263399 DOI: 10.1111/hpb.12345] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
5 Harper AM, Edwards E, Washburn WK, Heimbach J. An early look at the Organ Procurement and Transplantation Network explant pathology form data: OPTN Explant Pathology Form Data. Liver Transpl 2016;22:757-64. [DOI: 10.1002/lt.24441] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
6 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016;8:881-90. [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
7 Ecker BL, Hoteit MA, Forde KA, Hsu CC, Reddy KR, Furth EE, Siegelman ES, Habibollahi P, Ben-Josef E, Porrett PM, Abt PL, Shaked A, Olthoff KM, Levine MH. Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria. Transplantation. 2018;102:648-655. [PMID: 29319629 DOI: 10.1097/tp.0000000000002056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 5.3] [Reference Citation Analysis]
8 Ng KKC, Cheung TT, Wong TCL, Fung JYY, Dai JWC, Ma KW, She WH, Lo CM. Long-term survival comparison between primary transplant and upfront curative treatment with salvage transplant for early stage hepatocellular carcinoma. Asian J Surg 2019;42:433-42. [PMID: 30262437 DOI: 10.1016/j.asjsur.2018.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lerut J, Lai Q. Morphology does not tell us the entire story: biological behavior improves our ability to select patients with hepatocellular carcinoma waiting for liver transplantation. Hepatobiliary Pancreat Dis Int 2015;14:570-1. [PMID: 26663003 DOI: 10.1016/s1499-3872(15)60028-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Firl DJ, Kimura S, Mcvey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [DOI: 10.1002/hep.29907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
11 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Spoletini G, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66:1910-1919. [PMID: 28653750 DOI: 10.1002/hep.29342] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 12.8] [Reference Citation Analysis]
12 Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, Ben Bouallegue F, Assenat E, Mariano-Goulart D, Guiu B, Cassinotto C. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging 2019;100:689-97. [PMID: 31281074 DOI: 10.1016/j.diii.2019.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
13 Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, Kato T, Verna EC, Emond JC, Brown RS. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. Ann Surg. 2017;265:557-564. [PMID: 27611615 DOI: 10.1097/sla.0000000000001966] [Cited by in Crossref: 108] [Cited by in F6Publishing: 44] [Article Influence: 27.0] [Reference Citation Analysis]
14 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 26.0] [Reference Citation Analysis]
15 Liu B, Teng F, Fu H, Guo WY, Shi XM, Ni ZJ, Gao XG, Ma J, Fu ZR, Ding GS. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 2015;15:138. [PMID: 26472203 DOI: 10.1186/s12876-015-0364-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Dinorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Annals of Surgery 2020;271:616-24. [DOI: 10.1097/sla.0000000000003253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
17 Lee HW, Song G, Lee S, Kim JM, Joh J, Han DH, Kim SI, Kim SH, Kim D, Cho JY, Suh K. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma: Lee et al. Liver Transpl 2018;24:1243-51. [DOI: 10.1002/lt.25056] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
18 Rudnick SR, Russo MW. Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2018;12:265-75. [PMID: 29231769 DOI: 10.1080/17474124.2018.1417035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
19 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
20 Bhatti ABH, Qureshi AI, Tahir R, Dar FS, Khan NY, Zia HH, Riyaz S, Rana A. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer. 2020;20:754. [PMID: 32787864 DOI: 10.1186/s12885-020-07238-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
21 Xu X, Pu X, Jiang L, Huang Y, Yan L, Yang J, Wen T, Li B, Wu H, Wang W. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria. J Cancer Res Clin Oncol 2021;147:607-18. [PMID: 32852635 DOI: 10.1007/s00432-020-03364-x] [Reference Citation Analysis]
22 de'Angelis N, Landi F, Nencioni M, Palen A, Lahat E, Salloum C, Compagnon P, Lim C, Costentin C, Calderaro J. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Prog Transplant. 2016;. [PMID: 27555074 DOI: 10.1177/1526924816664083] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
23 Sacco R, Antonucci M, Bresci G, Corti A, Giacomelli L, Mismas V, Rainieri M, Romano A, Eggenhoffner R, Tumino E, Cabibbo G. Curative therapies for hepatocellular carcinoma: an update and perspectives. Expert Review of Anticancer Therapy 2016;16:169-75. [DOI: 10.1586/14737140.2016.1123625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Moteleub HNAE, Moety AAAE, Baddour NM, Shendidi AAE. Predictors for hepatocellular carcinoma recurrence after microwave ablation. Clin Exp Hepatol 2020;6:77-84. [PMID: 32728623 DOI: 10.5114/ceh.2019.95115] [Reference Citation Analysis]
25 Faitot F, Allard MA, Pittau G, Ciacio O, Adam R, Castaing D, Cunha AS, Pelletier G, Cherqui D, Samuel D, Vibert E. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. Hepatology 2015;62:179-87. [PMID: 25914217 DOI: 10.1002/hep.27864] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
26 Lai Q, Melandro F, Larghi Laureiro Z, Giovanardi F, Ginanni Corradini S, Ferri F, Hassan R, Rossi M, Mennini G. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis. World J Gastroenterol. 2018;24:1658-1665. [PMID: 29686473 DOI: 10.3748/wjg.v24.i15.1658] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
27 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00080-3. [PMID: 34384724 DOI: 10.1016/j.rgmxen.2021.07.006] [Reference Citation Analysis]
28 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 856] [Article Influence: 526.7] [Reference Citation Analysis]
29 Nakao K, Ichikawa T. Recent topics on α-fetoprotein. Hepatol Res. 2013;43:820-825. [PMID: 23347387 DOI: 10.1111/hepr.12052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
30 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
31 Moeckli B, Majno P, Orci LA, Peloso A, Toso C. Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective. Semin Liver Dis 2021;41:172-81. [PMID: 33957694 DOI: 10.1055/s-0041-1723032] [Reference Citation Analysis]
32 Kluger MD, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, Luciani A, Van Nhieu JT, Azoulay D, Cherqui D. Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62:1131-1140. [PMID: 25529622 DOI: 10.1016/j.jhep.2014.12.018] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
33 Daoud A, Soliman K, Teeter L, Ali H, Graviss EA, Mogawer S, Sholkamy A, El-Shazli M, Gaber AO. Alpha-Fetoprotein as a Modifier of Anatomic Criteria for Transplantation of HCC Patients. Transplant Proc 2021;53:833-8. [PMID: 33589231 DOI: 10.1016/j.transproceed.2021.01.024] [Reference Citation Analysis]
34 Burra P, Zanetto A, Germani G. Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E46. [PMID: 29425151 DOI: 10.3390/cancers10020046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
35 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
36 Lai Q, Lerut J. α-Fetoprotein and hepatocellular cancer recurrence: a paradigm of the chaos theory. Liver Transpl. 2014;20:1283. [PMID: 25060782 DOI: 10.1002/lt.23962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Mazzola A, Costantino A, Petta S, Bartolotta TV, Raineri M, Sacco R, Brancatelli G, Cammà C, Cabibbo G. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol 2015;11:2923-36. [PMID: 26414336 DOI: 10.2217/fon.15.239] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
38 Golse N, El Bouyousfi A, Marques F, Bancel B, Mohkam K, Ducerf C, Merle P, Sebagh M, Castaing D, Sa Cunha A, Adam R, Cherqui D, Vibert E, Mabrut J. Large hepatocellular carcinoma: Does fibrosis really impact prognosis after resection? Journal of Visceral Surgery 2018;155:265-73. [DOI: 10.1016/j.jviscsurg.2017.10.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
40 Bakr S, Echegaray S, Shah R, Kamaya A, Louie J, Napel S, Kothary N, Gevaert O. Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study. J Med Imaging (Bellingham) 2017;4:041303. [PMID: 28840174 DOI: 10.1117/1.JMI.4.4.041303] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
41 Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg. 2016;263:842-850. [PMID: 26779979 DOI: 10.1097/sla.0000000000001578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 23] [Article Influence: 11.8] [Reference Citation Analysis]
42 Adhoute X, Pénaranda G, Raoul JL, Bourlière M. Usefulness of the MESH score in a European hepatocellular carcinoma cohort. World J Hepatol 2017;9:711-4. [PMID: 28596819 DOI: 10.4254/wjh.v9.i15.711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhao T, Jia L, Li J, Ma C, Wu J, Shen J, Dang L, Zhu B, Li P, Zhi Y, Lan R, Xu Y, Hao Z, Chai Y, Li Q, Hu L, Sun S. Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. Front Oncol 2020;10:496. [PMID: 32426269 DOI: 10.3389/fonc.2020.00496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
44 Desai CS, Barritt AS 4th. Dynamic α-Fetoprotein Response-Are We Ready to Change the Dynamics of Hepatocellular Carcinoma Liver Transplant Practice? JAMA Surg 2021;156:567-8. [PMID: 33950253 DOI: 10.1001/jamasurg.2021.0955] [Reference Citation Analysis]
45 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
46 Ren Q, Fu S, Wang D, Ju W, He X. Prognostic Value of Preoperative Serum Leucine Aminopeptidases in Hepatocellular Carcinoma Patients Who Underwent Liver Transplantation. Cancer Manag Res 2021;13:1053-66. [PMID: 33574703 DOI: 10.2147/CMAR.S292128] [Reference Citation Analysis]
47 Orci LA, Lacotte S, Oldani G, Slits F, De Vito C, Crowe LA, Rubbia-Brandt L, Vallée JP, Morel P, Toso C. Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. Br J Surg 2016;103:417-26. [PMID: 26891212 DOI: 10.1002/bjs.10080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
48 Togashi J, Akamastu N, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital. Hepatobiliary Surg Nutr. 2016;5:399-407. [PMID: 27826554 DOI: 10.21037/hbsn.2016.08.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
49 Nitta H, Allard MA, Sebagh M, Ciacio O, Pittau G, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Guettier C, Lewin M, Samuel D, Baba H, Adam R. Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:2568-76. [PMID: 31054040 DOI: 10.1245/s10434-019-07365-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
50 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
51 Invenizzi F, Iavarone M, Donato MF, Mazzucco A, Torre M, Conforti S, Rimessi A, Zavaglia C, Schiavon M, Comacchio G, Rea F, Boetto R, Cillo U, Dondossola D, De Carlis L, Lampertico P, Nosotti M, Mendogni P. Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience. Front Oncol. 2020;10:381. [PMID: 32351877 DOI: 10.3389/fonc.2020.00381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther 2020;20:63-74. [PMID: 31910040 DOI: 10.1080/14737140.2020.1712198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
53 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Reference Citation Analysis]
54 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Reference Citation Analysis]
55 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Reference Citation Analysis]
56 Durand F, Antoine C, Soubrane O. Liver Transplantation in France. Liver Transpl 2019;25:763-70. [DOI: 10.1002/lt.25419] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
57 Debette-gratien M, Woillard J, Picard N, Sebagh M, Loustaud-ratti V, Sautereau D, Samuel D, Marquet P. Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. Transplantation 2016;100:2129-37. [DOI: 10.1097/tp.0000000000001394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 3.4] [Reference Citation Analysis]
58 Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67. [PMID: 27169841 DOI: 10.1111/liv.13159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
59 Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018;10:41-50. [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
60 Menahem B, Dejardin O, Alves A, Launay L, Lubrano J, Duvoux C, Laurent A, Launoy AG; French Liver Transplantation Group*. Socioeconomic Deprivation Does Not Impact Liver Transplantation Outcome for HCC: A Survival Analysis From a National Database. Transplantation 2021;105:1061-8. [PMID: 32541559 DOI: 10.1097/TP.0000000000003340] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Borentain P, Gregoire E, Louis G, Gerolami R. Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy. Liver Int 2016;36:1393. [PMID: 27349954 DOI: 10.1111/liv.13190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
62 Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64:2077-2088. [PMID: 27178646 DOI: 10.1002/hep.28643] [Cited by in Crossref: 148] [Cited by in F6Publishing: 121] [Article Influence: 29.6] [Reference Citation Analysis]
63 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Gelu-Simeon M, Lewin M, Ostos M, Bayan T, Beso Delgado M, Teicher E, Layese R, Roudot-Thoraval F, Fontaine H, Sobesky R, Salmon-Céron D, Samuel D, Seror O, Nahon P, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 Prethevic, ANRS CO13 HepaVih and ANRS CO12 CirVir Study Groups. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. Liver Int 2019;39:136-46. [PMID: 29947467 DOI: 10.1111/liv.13921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
65 Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Ann Surg 2018;268:868-75. [PMID: 30080736 DOI: 10.1097/SLA.0000000000002889] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 25.5] [Reference Citation Analysis]
66 Toso C, Meeberg G, Andres A, Shore C, Saunders C, Bigam DL, Shapiro AMJ, Compagnon P, Berney T, Majno P, Kneteman N. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. Transpl Int 2019;32:163-72. [PMID: 30152891 DOI: 10.1111/tri.13337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
67 She WH, Chan ACY, Cheung TT, Lo CM, Chok KSH. Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels. World J Hepatol. 2018;10:308-318. [PMID: 29527266 DOI: 10.4254/wjh.v10.i2.308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
68 Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79. [PMID: 29140601 DOI: 10.1002/lt.24977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
69 Li H, Yang Z, Li R, Lu S, Lu W. Regorafenib Combined With Sirolimus Achieves Successful Treatment of Diffuse Double Lung Metastasis After Liver Transplantation in Giant Liver Cancer Beyond Transplantation Criteria: A Case Report. Transplant Proc 2020;52:634-7. [PMID: 32035675 DOI: 10.1016/j.transproceed.2019.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Piñero F, Thompson MA, Diaz Telli F, Trentacoste J, Padín C, Mendizabal M, Colaci C, Gonzalez Campaña A, Pages J, Montal S, Barreiro M, Fauda M, Podestá G, Perotti JP, Silva M. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Ann Hepatol 2020;19:662-7. [PMID: 32683095 DOI: 10.1016/j.aohep.2020.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, Hsu HW, Lim WX, Huang TL, Cheng YF. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19:74. [PMID: 31730015 DOI: 10.1186/s40644-019-0264-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Savier E, Lim C, Rayar M, Orlando F, Boudjema K, Mohkam K, Lesurtel M, Mabrut JY, Pittau G, Begdadi N, Cherqui D, Adam R, Dondero F, Sepulveda A, Soubrane O, Bucur P, Barbier L, Salame E, Jasseron C, Antoine C, Riou B, Scatton O. Favorable Outcomes of Liver Transplantation from Controlled Circulatory Death Donors Using Normothermic Regional Perfusion Compared to Brain Death Donors.Transplantation. 2020;104:1943-1951. [PMID: 32639402 DOI: 10.1097/TP.0000000000003372] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
74 de la Fuente S, Citores MJ, Lucena JL, Muñoz P, Cuervas-Mons V. TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. Biomark Med 2019;13:995-1004. [PMID: 31317790 DOI: 10.2217/bmm-2019-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
75 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
76 Refaat R, Basha MAA, Hassan MS, Hussein RS, El Sammak AA, El Sammak DAEA, Radwan MHS, Awad NM, Saad El-Din SA, Elkholy E, Ibrahim DRD, Saleh SA, Montasser IF, Said H. Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma. Eur Radiol. 2018;28:5356-5367. [PMID: 29948070 DOI: 10.1007/s00330-018-5425-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852-859. [PMID: 26658686 DOI: 10.1016/j.jhep.2015.11.033] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 10.7] [Reference Citation Analysis]
78 Rodríguez-perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-caparrós C, O’beirne J, Poyato-gonzález A, Ferrín-sánchez G, Montero-álvarez JL, Patch D, Thorburn D, Briceño J, De la Mata M, Burroughs AK. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. Journal of Hepatology 2013;59:1193-9. [DOI: 10.1016/j.jhep.2013.07.012] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 12.0] [Reference Citation Analysis]
79 Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer. 2014;120:2150-2157. [PMID: 24723129 DOI: 10.1002/cncr.28706] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
80 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673-687. [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
81 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
82 Mulé S, Chalaye J, Legou F, Tenenhaus A, Calderaro J, Galletto Pregliasco A, Laurent A, Kharrat R, Amaddeo G, Regnault H, Tacher V, Kobeiter H, Itti E, Luciani A. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT. Eur Radiol 2020;30:5348-57. [PMID: 32405753 DOI: 10.1007/s00330-020-06923-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
83 Allaire M, Nault J. Advances in management of hepatocellular carcinoma. Current Opinion in Oncology 2017;29:288-95. [DOI: 10.1097/cco.0000000000000378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
84 Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Adam R. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transpl. 2017;23:440-447. [PMID: 28187493 DOI: 10.1002/lt.24742] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
85 Boussouar S, Itti E, Lin SJ, Decaens T, Evangelista E, Chiaradia M, Chalaye J, Baranes L, Calderaro J, Laurent A. Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. Cancer Imaging. 2016;16:4. [PMID: 26883745 DOI: 10.1186/s40644-016-0062-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
86 Chagas AL, Mattos AA, Diniz MA, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Ann Hepatol 2021;22:100294. [PMID: 33276136 DOI: 10.1016/j.aohep.2020.100294] [Reference Citation Analysis]
87 Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 2015;62:158-165. [PMID: 25777590 DOI: 10.1002/hep.27787] [Cited by in Crossref: 135] [Cited by in F6Publishing: 113] [Article Influence: 22.5] [Reference Citation Analysis]
88 Lamerz R. Are Biomarkers Still Helpful in Hepatocellular Carcinoma? Digestion 2013;87:118-20. [DOI: 10.1159/000346282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 72] [Article Influence: 90.0] [Reference Citation Analysis]
90 Bhangui P, Saigal S, Gautam D, Piplani T, Choudhary N, Chaudhary R, Yadav S, Thiagarajan S, Rastogi A, Saraf N, Nundy S, Soin AS. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria. Liver Transpl 2021;27:209-21. [PMID: 33253492 DOI: 10.1002/lt.25956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Unzueta A, Cabrera R. Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. Clinics in Liver Disease 2017;21:231-51. [DOI: 10.1016/j.cld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 20.5] [Reference Citation Analysis]
93 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 17.3] [Reference Citation Analysis]
95 Lee HW, Suh KS. Liver transplantation for advanced hepatocellular carcinoma. Clin Mol Hepatol 2016;22:309-18. [PMID: 27729631 DOI: 10.3350/cmh.2016.0042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
96 Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36. [PMID: 30166858 DOI: 10.3748/wjg.v24.i32.3626] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
97 Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, Mentha G, Toso C. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg 2015;102:1250-7. [PMID: 26098966 DOI: 10.1002/bjs.9868] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
98 Yoo T, Lee KW, Yi NJ, Choi YR, Kim H, Suh SW, Jeong JH, Lee JM, Suh KS. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation. J Korean Med Sci 2016;31:1049-54. [PMID: 27366001 DOI: 10.3346/jkms.2016.31.7.1049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
99 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
100 Mohkam K, Golse N, Bonal M, Ledochowski S, Rode A, Selmaji IE, Merle P, Ducerf C, Mornex F, Mabrut J. Conformal radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma: is it safe? Future Oncology 2016;12:1577-86. [DOI: 10.2217/fon-2016-0083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
101 Court CM, Harlander-Locke MP, Markovic D, French SW, Naini BV, Lu DS, Raman SS, Kaldas FM, Zarrinpar A, Farmer DG, Finn RS, Sadeghi S, Tomlinson JS, Busuttil RW, Agopian VG. Determination of hepatocellular carcinoma grade by needle biopsy is unreliable for liver transplant candidate selection. Liver Transpl. 2017;23:1123-1132. [PMID: 28688158 DOI: 10.1002/lt.24811] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
102 Rhu J, Kim JM, Choi GS, Kwon CHD, Joh JW. Validation of the α-fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population. Transplantation 2018;102:1316-22. [PMID: 29470357 DOI: 10.1097/TP.0000000000002136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
103 Polat KY, Acar S, Gencdal G, Yazar S, Kargi A, Donmez R, Aslan S, Kavlak ME, Arikan C, Akyildiz M. Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience. Transplantation Proceedings 2020;52:259-64. [DOI: 10.1016/j.transproceed.2019.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
104 Viveiros A, Zoller H, Finkenstedt A. Hepatocellular carcinoma: when is liver transplantation oncologically futile? Transl Gastroenterol Hepatol 2017;2:63. [PMID: 28815223 DOI: 10.21037/tgh.2017.07.03] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
105 Artzner T, Michard B, Weiss E, Barbier L, Noorah Z, Merle J, Paugam‐burtz C, Francoz C, Durand F, Soubrane O, Pirani T, Theocharidou E, O’grady J, Bernal W, Heaton N, Salamé E, Bucur P, Barraud H, Lefebvre F, Serfaty L, Besch C, Bachellier P, Schneider F, Levesque E, Faitot F. Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors. Am J Transplant 2020;20:2437-48. [DOI: 10.1111/ajt.15852] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 18.0] [Reference Citation Analysis]
106 Müller PC, Kabacam G, Vibert E, Germani G, Petrowsky H. Current status of liver transplantation in Europe. International Journal of Surgery 2020;82:22-9. [DOI: 10.1016/j.ijsu.2020.05.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
107 Strassburg CP. HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations? Visc Med 2016;32:263-71. [PMID: 27722163 DOI: 10.1159/000446385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
108 Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552-559. [PMID: 27899297 DOI: 10.1016/j.jhep.2016.10.038] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 15.0] [Reference Citation Analysis]
109 Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, Kang SH, Yim SY, Suh SJ, An H, Yim HJ, Yeon JE, Byun KS, Um SH. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-74. [PMID: 26332049 DOI: 10.1111/jgh.13152] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
110 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 273] [Article Influence: 61.3] [Reference Citation Analysis]
111 Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transplant. 2016;21:231-237. [PMID: 26918880 DOI: 10.1097/mot.0000000000000294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
112 Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, Vicentin I, Garanzini E, Mazzaferro V, De Carlis L, Golfieri R, Spreafico C, Vanzulli A, Buscemi V, Ravaioli M, Ercolani G, Pinna AD, Cescon M. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology 2020;73:342-8. [DOI: 10.1016/j.jhep.2020.03.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
113 Shen J, Tang L, Zhang X, Peng W, Wen T, Li C, Yang J, Liu G. A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR). Front Oncol 2019;9:817. [PMID: 31612101 DOI: 10.3389/fonc.2019.00817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
114 Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int. 2017;37:317-327. [PMID: 27634369 DOI: 10.1111/liv.13255] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
115 Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, Wu L, Geng L, Ke Q, Gao F, Tu Z, Wang W, Zhang M, Shen Y, Xie H, Jiang W, Wang H, Zheng S. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2016;65:1035-1041. [PMID: 25804634 DOI: 10.1136/gutjnl-2014-308513] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 13.8] [Reference Citation Analysis]
116 Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, Taketomi A, Takahara T, Wakabayashi G, Nakanishi C, Kawagishi N, Kenjo A, Gotoh M, Toyoki Y, Hakamada K, Ohtsuka M, Akamatsu N, Kokudo N, Takeda K, Endo I, Takamura H, Okajima H, Wada H, Kubo S, Kuramitsu K, Ku Y, Ishiyama K, Ohdan H, Ito E, Maehara Y, Honda M, Inomata Y, Furukawa H, Uemoto S, Yamaue H, Miyazaki M, Takada T; LTx-PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: A Japanese multicenter study. J Hepatobiliary Pancreat Sci. 2017;24:49-57. [PMID: 27806426 DOI: 10.1002/jhbp.412] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
117 Teng F, Han QC, Ding GS, Ni ZJ, Fu H, Guo WY, Shi XM, Gao XG, Ma J, Fu ZR. Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep 2015;5:11733. [PMID: 26096817 DOI: 10.1038/srep11733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
118 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 128] [Article Influence: 36.5] [Reference Citation Analysis]
119 Yoshizumi T, Shirabe K, Mori M. It is time to abandon the Milan criteria. Hepatobiliary Surg Nutr 2019;8:56-8. [PMID: 30881966 DOI: 10.21037/hbsn.2018.10.08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, Poyanli A, Gulluoglu M, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol 2018;10:51-61. [PMID: 29399278 DOI: 10.4254/wjh.v10.i1.51] [Reference Citation Analysis]
121 Barbier L, Cauchy F. “Hors Tour” Liver Grafts: A Step Towards Optimal Donor and Recipient Matching? World J Surg 2020;44:925-6. [DOI: 10.1007/s00268-019-05341-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg. 2015;220:416-427. [PMID: 25690672 DOI: 10.1016/j.jamcollsurg.2014.12.025] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 18.9] [Reference Citation Analysis]
123 Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol 2016;22:3325-34. [PMID: 27022214 DOI: 10.3748/wjg.v22.i12.3325] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
124 Manzia TM, Lai Q, Iesari S, Perera MTPR, Komuta M, Carvalheiro A, Shah T, Angelico R, Quaranta C, Nicolini D, Montalti R, Scarpelli M, Palmieri G, Orlacchio A, Vivarelli M, Angelico M, Lerut J, Tisone G. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. Transpl Int. 2018;. [PMID: 29572974 DOI: 10.1111/tri.13153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
125 Hong CM, Ahn BC, Jang YJ, Jeong SY, Lee SW, Lee J. Prognostic Value of Metabolic Parameters of 18F-FDG PET/CT and Apparent Diffusion Coefficient of MRI in Hepatocellular Carcinoma. Clin Nucl Med 2017;42:95-9. [PMID: 27941378 DOI: 10.1097/RLU.0000000000001478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
126 Dodson RM, He J, Pawlik TM. Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options. Future Oncology 2014;10:587-607. [DOI: 10.2217/fon.13.225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
127 Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018;154:128-139. [PMID: 28989060 DOI: 10.1053/j.gastro.2017.09.025] [Cited by in Crossref: 178] [Cited by in F6Publishing: 138] [Article Influence: 44.5] [Reference Citation Analysis]
128 Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer. 2014;3:108-118. [PMID: 24945001 DOI: 10.1159/000343866] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
129 Mohkam K, Dumont PN, Manichon AF, Jouvet JC, Boussel L, Merle P, Ducerf C, Lesurtel M, Rode A, Mabrut JY. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J Hepatol 2018;68:1172-80. [PMID: 29410287 DOI: 10.1016/j.jhep.2018.01.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
130 Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol 2016;8:1309-17. [PMID: 27872682 DOI: 10.4254/wjh.v8.i31.1309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
131 Tschuor C, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA;  Liver Allocation Study Group. Allocation of liver grafts worldwide - Is there a best system? J Hepatol. 2019;71:707-718. [PMID: 31199941 DOI: 10.1016/j.jhep.2019.05.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 15.0] [Reference Citation Analysis]
132 Gimson A. Development of a UK liver transplantation selection and allocation scheme. Current Opinion in Organ Transplantation 2020;25:126-31. [DOI: 10.1097/mot.0000000000000743] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
133 Liang L, Wang MD, Zhang YM, Zhang WG, Zhang CW, Lau WY, Shen F, Pawlik TM, Huang DS, Yang T. Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). J Hepatocell Carcinoma 2021;8:103-18. [PMID: 33748017 DOI: 10.2147/JHC.S289840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, Spada M, Nanni Costa A, Toniutto P; I-BELT (Italian Board of Experts in the Field of Liver Transplantation). A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model". Am J Transplant 2015;15:2552-61. [PMID: 26274338 DOI: 10.1111/ajt.13408] [Cited by in Crossref: 98] [Cited by in F6Publishing: 82] [Article Influence: 16.3] [Reference Citation Analysis]
135 Chopinet S, Grégoire E, Bollon E, Hak J, Palen A, Vidal V, Hardwigsen J, Le Treut Y. Short-term outcomes after major hepatic resection in patients with cirrhosis: a 75-case unicentric western experience. HPB 2019;21:352-60. [DOI: 10.1016/j.hpb.2018.07.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
136 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
137 Mehta N, Yao FY. Moving past “One size (and number) fits all” in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013;19:1055-1058. [PMID: 23959652 DOI: 10.1002/lt.23730] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
138 Antoine C, Legendre C. Organ Transplantation in France. Transplantation 2017;101:445-8. [DOI: 10.1097/tp.0000000000001510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
139 Olthoff KM, Goldberg DS. The MoRAL Path Beyond Milan. Annals of Surgery 2016;263:851-2. [DOI: 10.1097/sla.0000000000001679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
140 Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Cirugía Española 2015;93:619-37. [DOI: 10.1016/j.ciresp.2015.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
141 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
142 Menahem B, Duvoux C, Ganne N, Mallat A, Seror O, Calderaro J, Launoy G, Alves A, Cherqui D, Luciani A, Laurent A. Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP-Score. World J Surg 2019;43:221-9. [DOI: 10.1007/s00268-018-4769-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Grąt M, Stypułkowski J, Morawski M, Wronka KM, Wasilewicz M, Lewandowski Z, Grąt K, Wójcik Z, Patkowski W, Zieniewicz K. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. Ann Surg 2020;271:1124-31. [PMID: 30601254 DOI: 10.1097/SLA.0000000000003176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
144 Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH, Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21:599-606. [PMID: 25789635 DOI: 10.1002/lt.24117] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 10.4] [Reference Citation Analysis]
145 Giretti G, Barbier L, Bucur P, Marques F, Perarnau JM, Ferrandière M, Tellier AC, Kerouredan V, Altieri M, Causse X, Debette-Gratien M, Silvain C, Salamé E. Recipient Selection for Optimal Utilization of Discarded Grafts in Liver Transplantation. Transplantation 2018;102:775-82. [PMID: 29298235 DOI: 10.1097/TP.0000000000002069] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
146 Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, Antonelli B, Airoldi A, Manini MA, Sangiovanni A, Rossi G, Donato MF, Saverio Belli L, Lampertico P. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation. Transplantation 2020;104:568-74. [DOI: 10.1097/tp.0000000000002955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 10.0] [Reference Citation Analysis]
147 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
148 Cusumano C, De Carlis L, Centonze L, Lesourd R, Levi Sandri GB, Lauterio A, De Carlis R, Ferla F, Di Sandro S, Camus C, Jézéquel C, Bardou-Jacquet E, Rayar M. Advanced donor age does not increase risk of hepatocellular carcinoma recurrence after liver transplantation: a retrospective two-centre analysis using competing risk analysis. Transpl Int 2021. [PMID: 34145653 DOI: 10.1111/tri.13950] [Reference Citation Analysis]
149 Ogawa K, Takada Y. Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol 2016;1:35. [PMID: 28138602 DOI: 10.21037/tgh.2016.04.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
150 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
151 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J;  European Hepatocellular Cancer Liver Transplant Study Group. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl. 2019;25:1023-1033. [PMID: 31087772 DOI: 10.1002/lt.25492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
152 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 123] [Article Influence: 20.7] [Reference Citation Analysis]
153 Levi Sandri GB, Rayar M, Qi X, Lucatelli P. Liver transplant for patients outside Milan criteria. Transl Gastroenterol Hepatol 2018;3:81. [PMID: 30505968 DOI: 10.21037/tgh.2018.10.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
154 Costentin CE, Amaddeo G, Decaens T, Boudjema K, Bachellier P, Muscari F, Salame E, Bernard PH, Francoz C, Dharancy S, Vanlemmens C, Radenne S, Dumortier J, Hilleret MN, Chazouilleres O, Pageaux GP, Calderaro J, Laurent A, Roudot-Thoraval F, Group CDFLTFS. Prediction of hepatocellular carcinoma recurrence after liver transplantation: comparison of 4 explant-based prognostic models. Liver Int. 2017;37:717-726. [PMID: 28199760 DOI: 10.1111/liv.13388] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
155 Bhatti ABH, Waheed A, Khan NA. Living Donor Liver Transplantation for Hepatocellular Carcinoma: Appraisal of the United Network for Organ Sharing Modified TNM Staging. Front Surg 2020;7:622170. [PMID: 33553240 DOI: 10.3389/fsurg.2020.622170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Zhou PY, Yang CP, Tang Z, Yi Y, Liu WR, Tian MX, Huang JL, Gan W, Jiang XF, Liu G, Wang H, Tao CY, Fang Y, Qu WF, Zhou C, Guan RY, Sun BY, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Gong GZ, Shi YH, Qiu SJ. Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging (Albany NY). 2019;11:11111-11123. [PMID: 31829979 DOI: 10.18632/aging.102513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
157 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
158 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
159 Allard MA, Sa Cunha A, Ruiz A, Vibert E, Sebagh M, Castaing D, Adam R. The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome. J Gastrointest Surg. 2014;18:701-708. [PMID: 24402605 DOI: 10.1007/s11605-013-2433-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
160 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
161 Lai Q, Lerut JP. Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant. 2014;19:229-234. [PMID: 24811435 DOI: 10.1097/mot.0000000000000085] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
162 Grąt M, Wronka KM, Stypułkowski J, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Grąt K, Patkowski W, Krawczyk M. The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol 2017;24:526-34. [PMID: 27531306 DOI: 10.1245/s10434-016-5500-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
163 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 13.2] [Reference Citation Analysis]
164 Grąt M, Kornasiewicz O, Lewandowski Z, Hołówko W, Grąt K, Kobryń K, Patkowski W, Zieniewicz K, Krawczyk M. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014;38:2698-707. [PMID: 24858191 DOI: 10.1007/s00268-014-2647-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
165 Montalvá EM, Cantos M, Boscà A, Rubín A, Vinaixa C, Granero P, Maupoey J, López-Andújar R. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence. Transplant Proc 2016;48:2966-8. [PMID: 27932120 DOI: 10.1016/j.transproceed.2016.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
166 Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49. [PMID: 31316788 DOI: 10.1177/2050640619840221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
167 Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. Journal of Hepatology 2014;60:290-7. [DOI: 10.1016/j.jhep.2013.10.010] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
168 Lee E, Johnston CJC, Oniscu GC. The trials and tribulations of liver allocation. Transpl Int 2020;33:1343-52. [PMID: 32722866 DOI: 10.1111/tri.13710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Shan Q, Chen J, Zhang T, Yan R, Wu J, Shu Y, Kang Z, He B, Zhang Z, Wang J. Evaluating histologic differentiation of hepatitis B virus-related hepatocellular carcinoma using intravoxel incoherent motion and AFP levels alone and in combination. Abdom Radiol (NY) 2017;42:2079-88. [PMID: 28337521 DOI: 10.1007/s00261-017-1107-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
170 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
171 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00002-1. [PMID: 33676785 DOI: 10.1016/j.rgmx.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Lei JY, Wang WT, Yan LN. “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013;19:8093-8098. [PMID: 24307805 DOI: 10.3748/wjg.v19.i44.8093] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
173 Wang LY, Zheng SS. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 2018;19:497-504. [PMID: 29971988 DOI: 10.1631/jzus.B1700156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
174 Ince V, Ara C, Yilmaz S. Malatya and Other Criteria for Liver Transplantation in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1118-21. [PMID: 32860615 DOI: 10.1007/s12029-020-00484-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Ali MA, Li WF, Wang JH, Lin CC, Chen YJ, Lin TL, Lin TS, Lu SN, Wang CC, Chen CL. Impact of pathological features of primary hepatocellular carcinoma on the outcomes of intrahepatic recurrence management: single center experience from Southern Taiwan. HPB (Oxford) 2016;18:851-60. [PMID: 27567971 DOI: 10.1016/j.hpb.2016.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
176 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangui P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020;12:E452. [PMID: 32075133 DOI: 10.3390/cancers12020452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
177 Mazzotta AD, Pascale A, Cano L, Rosmorduc O, Allard MA, Sa Cunha A, Adam R, Cherqui D, Vibert E, Golse N. Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha-fetoprotein score: a new prognostic risk factor. Transpl Int 2021;34:954-63. [PMID: 33660346 DOI: 10.1111/tri.13858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
178 Parisi I, Tsochatzis E, Wijewantha H, Rodríguez-Perálvarez M, De Luca L, Manousou P, Fatourou E, Pieri G, Papastergiou V, Davies N. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within Milan criteria. Liver Transpl. 2014;20:1327-1335. [PMID: 25088400 DOI: 10.1002/lt.23969] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
179 Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol 2019;11:261-72. [PMID: 30967904 DOI: 10.4254/wjh.v11.i3.261] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
180 Vitale A, Scolari F, Bertacco A, Gringeri E, D'Amico F, Bassi D, D'Amico FE, Angeli P, Burra P, Lai Q, Cillo U. Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy? Cancers (Basel) 2021;13:2406. [PMID: 34067521 DOI: 10.3390/cancers13102406] [Reference Citation Analysis]
181 Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-Based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation 2020. [PMID: 33323764 DOI: 10.1097/TP.0000000000003575] [Reference Citation Analysis]
182 Lerut J, Iesari S, Foguenne M, Lai Q. Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol 2017;2:80. [PMID: 29167827 DOI: 10.21037/tgh.2017.09.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
183 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
184 Takada Y, Tohyama T, Watanabe J. Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. J Hepatobiliary Pancreat Sci 2015;22:279-86. [PMID: 25408520 DOI: 10.1002/jhbp.195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
185 Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK Jr, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-1977. [PMID: 25689978 DOI: 10.1002/hep.27752] [Cited by in Crossref: 217] [Cited by in F6Publishing: 153] [Article Influence: 36.2] [Reference Citation Analysis]
186 Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, Castaing D, Cherqui D, Irtan S, Calmus Y, Chazouillères O, Soubrane O, Luciani A, Feray C. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study. Annals of Surgery 2017;266:1035-44. [DOI: 10.1097/sla.0000000000001986] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
187 Koch C, Bette T, Waidmann O, Filmann N, Schrecker C, Trojan J, Weiler N, Vermehren J, Schnitzbauer AA, Bechstein WO, Zeuzem S, Herrmann E, Welker MW. AFP ratio predicts HCC recurrence after liver transplantation. PLoS One. 2020;15:e0235576. [PMID: 32614912 DOI: 10.1371/journal.pone.0235576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
188 Al-Ameri AAM, Wei X, Wen X, Wei Q, Guo H, Zheng S, Xu X. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2020;33:697-712. [PMID: 31985857 DOI: 10.1111/tri.13585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
189 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-485. [PMID: 26597456 DOI: 10.1016/j.jhep.2015.10.006] [Cited by in Crossref: 390] [Cited by in F6Publishing: 251] [Article Influence: 65.0] [Reference Citation Analysis]
190 Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med 2018;16:113. [PMID: 30064414 DOI: 10.1186/s12916-018-1110-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
191 Dumortier J, Besch C, Moga L, Coilly A, Conti F, Corpechot C, Bello AD, Faitot F, Francoz C, Hilleret MN, Houssel-Debry P, Jezequel C, Lavayssière L, Neau-Cransac M, Erard-Poinsot D, de Lédinghen V, Bourlière M, Bureau C, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION. Clin Res Hepatol Gastroenterol 2021;:101774. [PMID: 34332131 DOI: 10.1016/j.clinre.2021.101774] [Reference Citation Analysis]
192 Diaz G, Levitsky J, Oniscu G. Meeting report of the 2014 joint international congress of the International Liver Transplantation Society, Liver Intensive Care Group of Europe, and European Liver and Intestinal Association. Liver Transpl 2015;21:991-1000. [PMID: 25857840 DOI: 10.1002/lt.24144] [Reference Citation Analysis]
193 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
194 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Reference Citation Analysis]
195 Otto G, Pitton MB, Hoppe-Lotichius M, Weinmann A. Liver transplantation and BCLC classification: Limitations impede optimum treatment. Hepatobiliary Pancreat Dis Int 2021;20:6-12. [PMID: 33349607 DOI: 10.1016/j.hbpd.2020.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
196 Schiavo L, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. World J Gastroenterol. 2018;24:3330-3346. [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 15] [Article Influence: 9.7] [Reference Citation Analysis]
197 Song BG, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Kim JM, Joh JW, Choi GS. Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Transplant Proc 2020;52:881-8. [PMID: 32115240 DOI: 10.1016/j.transproceed.2020.01.037] [Reference Citation Analysis]
198 Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015;29:506-512. [PMID: 25777321 DOI: 10.1111/ctr.12542] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
199 Piñero F, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Coronel M, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Rubinstein F, Silva M; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018;30:376-83. [PMID: 29509603 DOI: 10.1097/MEG.0000000000001049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
200 Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting Mortality in Patients Developing Recurrent Hepatocellular Carcinoma After Liver Transplantation: Impact of Treatment Modality and Recurrence Characteristics. Ann Surg. 2017;266:118-125. [PMID: 27433914 DOI: 10.1097/sla.0000000000001894] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 12.8] [Reference Citation Analysis]
201 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 313] [Article Influence: 121.7] [Reference Citation Analysis]
202 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, Houessinon A. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta. 2016;463:39-44. [PMID: 27732875 DOI: 10.1016/j.cca.2016.10.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 82] [Article Influence: 18.2] [Reference Citation Analysis]
204 Xu X, Chen J, Wei Q, Liu Z, Yang Z, Zhang M, Wang G, Gao J, Yang Z, Guo W, Xing T, Shao Z, Xie Q, Zheng S. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition). Hepatobiliary & Pancreatic Diseases International 2019;18:307-12. [DOI: 10.1016/j.hbpd.2019.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
205 Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, Filipponi F, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA). Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. HPB (Oxford) 2018;20:768-75. [PMID: 29622402 DOI: 10.1016/j.hpb.2018.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
206 Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl 2020;26:1100-11. [PMID: 32531867 DOI: 10.1002/lt.25819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
207 Rodríguez-Perálvarez M, Gómez-Bravo MÁ, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J; Spanish Society of Liver Transplantation (SETH) Consensus Panel. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation 2021;105:602-7. [PMID: 32345868 DOI: 10.1097/TP.0000000000003281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
208 Ho C, Wu C, Lee P, Lai H, Ho M, Wu Y, Hu R. Analysis of the Risk Factors of Untransplantable Recurrence After Primary Curative Resection for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:2526-33. [DOI: 10.1245/s10434-013-2940-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
209 Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS Jr, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg 2021;156:559-67. [PMID: 33950167 DOI: 10.1001/jamasurg.2021.0954] [Reference Citation Analysis]
210 Nahon P, Aubé C, Moga L, Chalaye J, Guiu B, Luciani A, Rode A, Ronot M, Seror O, Soussan M, Sutter O, Bourlière M, Bureau C, de Lédinghen V, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. Clin Res Hepatol Gastroenterol 2021;:101766. [PMID: 34332137 DOI: 10.1016/j.clinre.2021.101766] [Reference Citation Analysis]
211 Pommergaard HC, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2016;30:171-177. [PMID: 27118303 DOI: 10.1016/j.trre.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
212 Wang J, Mao Y, Liu Y, Chen Z, Chen M, Lao X, Li S. Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment. J Gastrointest Surg. 2017;21:1128-1135. [PMID: 28397025 DOI: 10.1007/s11605-017-3420-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
213 Levi Sandri GB, Guerra F, Lai Q. Twenty years of Milan criteria: the wicked flee though no one pursues. Hepatobiliary Surg Nutr 2016;5:377-8. [PMID: 27500149 DOI: 10.21037/hbsn.2016.02.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
214 Pamecha V, Sinha PK, Rajendran V, Patil NS, Mohapatra N, Rastogi A, Patidar Y, Choudhury A. Living donor liver transplantation for hepatocellular carcinoma in Indian patients- Is the scenario different? Indian J Gastroenterol 2021;40:295-302. [PMID: 34019241 DOI: 10.1007/s12664-020-01138-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Assalino M, Terraz S, Grat M, Lai Q, Vachharajani N, Gringeri E, Bongini MA, Kulik L, Tabrizian P, Agopian V, Mehta N, Brustia R, Vitali GC, Andres A, Berney T, Mazzaferro V, Compagnon P, Majno P, Cillo U, Chapman W, Zieniewicz K, Scatton O, Toso C. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study. Transpl Int 2020;33:567-75. [PMID: 31994238 DOI: 10.1111/tri.13586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
216 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 732] [Article Influence: 112.9] [Reference Citation Analysis]
217 Vitale A, Lai Q, Farinati F, Bucci L, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Pawlik TM; On behalf of the Italian Liver Cancer (ITA.LI.CA) group. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. J Gastrointest Surg 2018;22:859-71. [DOI: 10.1007/s11605-018-3688-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
218 Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206-1213. [PMID: 29068145 DOI: 10.1111/ajt.14549] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
219 Feng J, Wu J, Zhu R, Feng D, Yu L, Zhang Y, Bu D, Li C, Zhou Y, Si L, Liu Y, Liang Z, Xu J, Wu T. Simple Risk Score for Prediction of Early Recurrence of Hepatocellular Carcinoma within the Milan Criteria after Orthotopic Liver Transplantation. Sci Rep. 2017;7:44036. [PMID: 28276470 DOI: 10.1038/srep44036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
220 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 30.0] [Reference Citation Analysis]
221 Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med 2018;55:57-65. [PMID: 29859798 DOI: 10.1016/j.ejim.2018.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
222 Al-Ameri AAM, Wei X, Lin L, Shao Z, Guo H, Xie H, Zhou L, Zheng S, Xu X. Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation. BMC Cancer. 2019;19:1136. [PMID: 31752756 DOI: 10.1186/s12885-019-6343-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol 2020;8:69-75. [PMID: 32274347 DOI: 10.14218/JCTH.2019.00050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
224 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Toso C, Majno P, Berney T, Morel P, Mentha G, Combescure C. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int. 2014;27:686-695. [PMID: 24649861 DOI: 10.1111/tri.12323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
226 Lo CM. Liver transplantation in 2012: Transplantation for liver cancer--more with better results. Nat Rev Gastroenterol Hepatol 2013;10:74-6. [PMID: 23296244 DOI: 10.1038/nrgastro.2012.257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
227 Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, Giovagnoni A, Vivarelli M, Lerut J. A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time–Radiological-response–Alpha-fetoprotein–INflammation (TRAIN) Score. Annals of Surgery 2016;264:787-96. [DOI: 10.1097/sla.0000000000001881] [Cited by in Crossref: 48] [Cited by in F6Publishing: 22] [Article Influence: 9.6] [Reference Citation Analysis]
228 Dirican A, Karakas S. What Should Be the Rules for Downstaging for Hepatocellular Carcinoma? J Gastrointest Cancer 2020;51:1148-51. [PMID: 32839945 DOI: 10.1007/s12029-020-00490-0] [Reference Citation Analysis]
229 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
230 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol. 2017;23:3690-3701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
232 Sposito C, Cucchetti A, Mazzaferro V. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. Dig Dis Sci 2019;64:1001-7. [DOI: 10.1007/s10620-019-05538-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
233 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Bhat M, Ghali P, Dupont B, Hilzenrat R, Tazari M, Roy A, Chaudhury P, Alvarez F, Carrier M, Bilodeau M. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics. J Hepatol 2017;66:374-81. [PMID: 27751840 DOI: 10.1016/j.jhep.2016.10.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
235 Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope; 7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018;102:816-822. [PMID: 29505494 DOI: 10.1097/tp.0000000000002094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
236 Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2018;. [PMID: 30391218 DOI: 10.1016/j.hpb.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
237 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
238 Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019;25:2591-602. [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
239 Ma KW, She WH, Chan ACY, Cheung TT, Fung JYY, Dai WC, Lo CM, Chok KSH. Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population. World J Gastrointest Oncol 2019;11:322-34. [PMID: 31040897 DOI: 10.4251/wjgo.v11.i4.322] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
240 Kim YR, Park S, Han S, Ahn JH, Kim S, Sinn DH, Jeong WK, Ko JS, Gwak MS, Kim GS. Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Sci Rep 2018;8:7157. [PMID: 29740069 DOI: 10.1038/s41598-018-25628-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
241 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
242 Nitta H, Younès A, El-Domiaty N, Karam V, Sobesky R, Vibert E, Coilly A, Maria Antonini T, De Martin E, Cherqui D, Baba H, Rosmorduc O, Adam R, Samuel D, Saliba F. High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients. Transpl Int 2021;34:1293-305. [PMID: 33932239 DOI: 10.1111/tri.13897] [Reference Citation Analysis]
243 Galuppo R, McCall A, Gedaly R. The role of bridging therapy in hepatocellular carcinoma. Int J Hepatol. 2013;2013:419302. [PMID: 24455285 DOI: 10.1155/2013/419302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
244 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015;7:2245-63. [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
245 Andres A, Oldani G, Berney T, Compagnon P, Line PD, Toso C. Transplantation for colorectal metastases: on the edge of a revolution. Transl Gastroenterol Hepatol. 2018;3:74. [PMID: 30363763 DOI: 10.21037/tgh.2018.08.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
246 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014.122] [Cited by in Crossref: 247] [Cited by in F6Publishing: 222] [Article Influence: 35.3] [Reference Citation Analysis]
247 Degroote H, Callebout E, Iesari S, Dekervel J, Schreiber J, Pirenne J, Verslype C, Ysebaert D, Michielsen P, Lucidi V, Moreno C, Detry O, Delwaide J, Troisi RI, Lerut JP, Van Vlierberghe H; Be-LIAC. Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium. Surg Oncol 2020;33:231-8. [PMID: 31630912 DOI: 10.1016/j.suronc.2019.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
248 Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Current Opinion in Organ Transplantation 2016;21:91-8. [DOI: 10.1097/mot.0000000000000282] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.6] [Reference Citation Analysis]
249 Nathani P, Gopal P, Rich N, Yopp A, Yokoo T, John B, Marrero J, Parikh N, Singal AG. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut 2021;70:401-7. [PMID: 32398224 DOI: 10.1136/gutjnl-2020-321040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
250 Dong H, Xiang S, Liang H, Li C, Zhang Z, Chen X. The niche of hepatic cancer stem cell and cancer recurrence. Medical Hypotheses 2013;80:666-8. [DOI: 10.1016/j.mehy.2013.01.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
251 Maccali C, Chagas AL, Boin I, Quiñonez E, Marciano S, Vilatobá M, Varón A, Anders M, Hoyos Duque S, Lima AS, Menendez J, Padilla‐machaca M, Poniachik J, Zapata R, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, Soza A, Fauda M, Perales SR, Vergara Sandoval R, Bermudez C, Beltran O, Arenas Hoyos I, Mccormack L, Mattera FJ, Gadano A, Parente García JH, Tani CM, Augusto Carneiro D’albuquerque L, Carrilho FJ, Silva M, Piñero F. Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort. Liver Int 2021;41:851-62. [DOI: 10.1111/liv.14736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
252 Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017;101:2071-2078. [PMID: 28353492 DOI: 10.1097/tp.0000000000001752] [Cited by in Crossref: 38] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
253 Wang LY, Zheng SS, Xu X, Wang WL, Wu J, Zhang M, Shen Y, Yan S, Xie HY, Chen XH, Jiang TA, Chen F. A score model for predicting post-liver transplantation survival in HBV cirrhosis-related hepatocellular carcinoma recipients: a single center 5-year experience. Hepatobiliary Pancreat Dis Int 2015;14:43-9. [PMID: 25655289 DOI: 10.1016/s1499-3872(15)60335-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
254 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020;10:297-306. [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Reference Citation Analysis]
255 De Martin E, Rayar M, Golse N, Dupeux M, Gelli M, Gnemmi V, Allard MA, Cherqui D, Sa Cunha A, Adam R, Coilly A, Antonini TM, Guettier C, Samuel D, Boudjema K, Boleslawski E, Vibert E. Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular‐Cholangiocarcinoma in the Setting of Cirrhosis. Liver Transpl 2020;26:785-98. [DOI: 10.1002/lt.25737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
256 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
257 Mahmud N, John B, Taddei TH, Goldberg DS. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality. Clin Transplant. 2019;33:e13634. [PMID: 31177570 DOI: 10.1111/ctr.13634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
258 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1603] [Article Influence: 707.3] [Reference Citation Analysis]
259 Lai Q, Iesari S, Melandro F, Mennini G, Rossi M, Lerut J. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol 2017;2:72. [PMID: 29034345 DOI: 10.21037/tgh.2017.09.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
260 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016;8:58-68. [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
261 El-Fattah MA. Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. Indian J Gastroenterol. 2017;36:117-125. [PMID: 28194604 DOI: 10.1007/s12664-017-0732-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
262 Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. Journal of Hepatology 2020;72:277-87. [DOI: 10.1016/j.jhep.2019.09.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
263 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
264 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-535. [PMID: 25091611 DOI: 10.1038/nrclinonc.2014] [Reference Citation Analysis]
265 Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006. [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 12.8] [Reference Citation Analysis]
266 Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. The Lancet Gastroenterology & Hepatology 2017;2:595-603. [DOI: 10.1016/s2468-1253(17)30106-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
267 Cascales-campos PA, Romero PR, Schneider MA, Lopez-lopez V, Navarro JL, Frutos L, Pons Miñano JA, Paricio PP. Positron emission tomography/computed tomography in patients with hepatocellular carcinoma undergoing liver transplantation. Useful, necessary or irrelevant? European Journal of Radiology 2017;91:155-9. [DOI: 10.1016/j.ejrad.2017.03.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
268 Zhao WJ, Zhu GQ, Wu YM, Wang WW, Bai BL. Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis. Onco Targets Ther 2019;12:10389-400. [PMID: 31819521 DOI: 10.2147/OTT.S224809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
269 Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation: Alpha-Fetoprotein Increase and m RECIST Progression. Liver Transpl 2013;19:1108-18. [DOI: 10.1002/lt.23706] [Cited by in Crossref: 121] [Cited by in F6Publishing: 108] [Article Influence: 15.1] [Reference Citation Analysis]
270 Zhang R, Xu L, Wen X, Zhang J, Yang P, Zhang L, Xue X, Wang X, Huang Q, Guo C, Shi Y, Niu T, Chen F. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.Quant Imaging Med Surg. 2019;9:1503-1515. [PMID: 31667137 DOI: 10.21037/qims.2019.09.07] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
271 Pommergaard HC, Rostved AA, Adam R, Rasmussen A, Salizzoni M, Bravo MAG, Cherqui D, De Simone P, Houssel-Debry P, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Thygesen LC. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer 2020;9:455-67. [PMID: 32999871 DOI: 10.1159/000507397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
272 Faitot F, Michard B, Artzner T. Organ allocation in the age of the algorithm: avoiding futile transplantation - utility in allocation. Curr Opin Organ Transplant 2020;25:305-9. [PMID: 32304427 DOI: 10.1097/MOT.0000000000000752] [Reference Citation Analysis]
273 Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U; for the Italian Liver Cancer group. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor: Utility-Based Patient Selection. Liver Transpl 2015;21:1250-8. [DOI: 10.1002/lt.24214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
274 Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun 2017;1:18-22. [PMID: 29404430 DOI: 10.1002/hep4.1014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
275 Dituri F, Serio G, Filannino D, Mascolo A, Sacco R, Villa E, Giannelli G. Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. Cancer Lett. 2014;353:264-271. [PMID: 25088578 DOI: 10.1016/j.canlet.2014.07.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
276 Cascales-campos P, Martinez-insfran L, Ramirez P, Ferreras D, Gonzalez-sanchez M, Sanchez-bueno F, Robles R, Pons J, Capel A, Parrilla P. Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It? Transplantation Proceedings 2018;50:591-4. [DOI: 10.1016/j.transproceed.2017.09.063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
277 Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, Mallat A, Launoy G, Laurent A. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017;23:836-844. [PMID: 28295992 DOI: 10.1002/lt.24758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
278 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, Mara KC, Harmsen WS, Theobald JP, Peters BE, Balsanek JG, Ward MM, Giama NH, Venkatesh SK, Harnois DM, Charlton MR, Yamada H, Algeciras-Schimnich A, Snyder MR, Therneau TM, Roberts LR. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018;24:1321-31. [PMID: 29599607 DOI: 10.3748/wjg.v24.i12.1321] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
280 Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, Kawasaki S, Uemoto S, Kokudo N, Hasegawa K, Ohdan H, Egawa H, Furukawa H, Todo S;  Japanese Liver Transplantation Society. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int. 2019;32:356-368. [PMID: 30556935 DOI: 10.1111/tri.13391] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
281 Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E, Neau-cransac M, Durand F, Houssel-debry P, Vanlemmens C, Pageaux G, Hardwigsen J, Eyraud D, Calmus Y, Di Giambattista F, Dumortier J, Conti F. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. Am J Transplant 2017;17:1843-52. [DOI: 10.1111/ajt.14212] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 11.3] [Reference Citation Analysis]
282 Xue J, Cao Z, Cheng Y, Wang J, Liu Y, Yang R, Li H, Jiang W, Li G, Zhao W, Zhang X. Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression. Cancer Lett 2020;471:12-26. [PMID: 31811908 DOI: 10.1016/j.canlet.2019.11.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
283 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 73] [Article Influence: 31.0] [Reference Citation Analysis]
284 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol. 2017;9:1322-1331. [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
285 Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging. Transplantation 2020;104:2334-45. [PMID: 32032291 DOI: 10.1097/TP.0000000000003162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
286 Varona MA, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D, Portero J, Bravo P, Barrera MA, Perera A. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84-89. [PMID: 25645778 DOI: 10.1016/j.transproceed.2014.12.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
287 Nitta H, Allard MA, Sebagh M, Karam V, Ciacio O, Pittau G, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Guettier C, Samuel D, Baba H, Adam R. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation. Surgery 2019;165:1168-75. [PMID: 30878140 DOI: 10.1016/j.surg.2019.01.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
288 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Ince V, Carr BI, Bag HG, Ersan V, Usta S, Koc C, Gonultas F, Sarici BK, Karakas S, Kutluturk K, Baskiran A, Yilmaz S. Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study. World J Gastrointest Surg 2020;12:520-33. [PMID: 33437403 DOI: 10.4240/wjgs.v12.i12.520] [Reference Citation Analysis]
290 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
291 Jamtani I, Lee KW, Choi Y, Choi Y, Lee JM, Han ES, Hong K, Choi GS, Kim JM, Yi NJ, Hong SK, Byun J, Hong SY, Suh S, Joh JW, Suh KS. Tailored Prediction Model of Survival after Liver Transplantation for Hepatocellular Carcinoma. J Clin Med 2021;10:2869. [PMID: 34203396 DOI: 10.3390/jcm10132869] [Reference Citation Analysis]
292 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
293 Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, Castells L, Sandroussi C, Bilbao I, Dopazo C, Grant DR, Lázaro JL, Caralt M, Ghanekar A, McGilvray ID, Lilly L, Cattral MS, Selzner M, Charco R, Greig PD. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. Ann Surg Oncol 2015;22:2286-94. [PMID: 25472651 DOI: 10.1245/s10434-014-4273-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
294 Lai Q, Levi Sandri GB, Lerut J. Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World J Hepatol. 2015;7:1899-1904. [PMID: 26244064 DOI: 10.4254/wjh.v7.i15.1899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
295 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
296 Dahlqvist G, Moreno C, Starkel P, Detry O, Coubeau L, Jochmans I. Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC). Acta Gastroenterol Belg 2021;84:347-59. [PMID: 34217187 DOI: 10.51821/84.2.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, Hey S, Blunsum A, Kelly S, Sturgeon C, Hayes PC. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS One. 2016;11:e0156801. [PMID: 27308823 DOI: 10.1371/journal.pone.0156801] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
298 Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology. 2007;46:1574-1585. [PMID: 17969047 DOI: 10.1002/hep.28139] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
299 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
300 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
301 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
302 Zhang T, Liu Y, Peng X, Fan J, Peng Z. Association between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation. Dis Markers 2017;2017:1754696. [PMID: 29162948 DOI: 10.1155/2017/1754696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
303 Antoine C, Jasseron C, Dondero F, Savier E; French National Steering Committee of Donors After Circulatory Death. Liver Transplantation From Controlled Donors After Circulatory Death Using Normothermic Regional Perfusion: An Initial French Experience. Liver Transpl 2020;26:1516-21. [PMID: 32531132 DOI: 10.1002/lt.25818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
304 Grąt K, Grąt M, Rowiński O, Patkowski W, Zieniewicz K, Pacho R. Accuracy of Computed Tomography in the Assessment of Milan Criteria in Liver Transplantation for Hepatocellular Carcinoma. Transplant Proc 2018;50:2002-5. [PMID: 30177097 DOI: 10.1016/j.transproceed.2018.02.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
305 Irtan S, Barbier L, Francoz C, Dondéro F, Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible? Hepatobiliary & Pancreatic Diseases International 2016;15:147-51. [DOI: 10.1016/s1499-3872(16)60069-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
306 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
307 Pauwels X, Azahaf M, Lassailly G, Sergent G, Buob D, Truant S, Boleslawski E, Louvet A, Gnemmi V, Canva V, Mathurin P, Pruvot F, Leteurtre E, Ernst O, Dharancy S. Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. Cardiovasc Intervent Radiol 2015;38:685-92. [DOI: 10.1007/s00270-014-0967-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
308 Kudo A, Matsumura S, Ban D, Irie T, Ochiai T, Tanaka S, Arii S, Tanabe M. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res 2014;44:E437-46. [PMID: 24690156 DOI: 10.1111/hepr.12335] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
309 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
310 Terasawa M, Allard MA, Golse N, Sa Cunha A, Cherqui D, Adam R, Saiura A, Vibert E. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis. Surgery 2020;167:425-31. [PMID: 31780050 DOI: 10.1016/j.surg.2019.09.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
311 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Ann Hepatol 2018;17:256-67. [PMID: 29469048 DOI: 10.5604/01.3001.0010.8648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
312 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, Mccormack L, Gadano A, Boin ISF, García P, Silva M. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clinics and Research in Hepatology and Gastroenterology 2018;42:443-52. [DOI: 10.1016/j.clinre.2018.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
313 Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis. J Surg Oncol 2015;112:72-9. [PMID: 26032085 DOI: 10.1002/jso.23944] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
314 Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant 2019;19:3176-84. [PMID: 31365177 DOI: 10.1111/ajt.15551] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
315 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 119] [Article Influence: 27.2] [Reference Citation Analysis]
316 Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology 2019;69:1193-205. [PMID: 30548884 DOI: 10.1002/hep.30413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
317 Kim DJ, Clark PJ, Heimbach J, Rosen C, Sanchez W, Watt K, Charlton MR. Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014;14:1383-1390. [PMID: 24801862 DOI: 10.1111/ajt.12684] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
318 Grąt M, Stypułkowski J, Patkowski W, Wronka KM, Bik E, Krasnodębski M, Masior Ł, Lewandowski Z, Wasilewicz M, Grąt K, Krawczyk M, Zieniewicz K. Challenging the principle of utility as a barrier for wider use of liver transplantation for hepatocellular cancer. Ann Surg Oncol 2017;24:3188-95. [PMID: 28695391 DOI: 10.1245/s10434-017-5989-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
319 Mourad M, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort - a retrospective study. Transpl Int 2021;34:535-45. [PMID: 33449394 DOI: 10.1111/tri.13819] [Reference Citation Analysis]
320 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
321 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
322 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
323 Winter A, Féray C, Audureau E, Écochard R, Jacquelinet C, Roudot-thoraval F, Duvoux C, Daurès J, Landais P. External validation of the Donor Risk Index and the Eurotransplant Donor Risk Index on the French liver transplantation registry. Liver Int 2017;37:1229-38. [DOI: 10.1111/liv.13378] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
324 De Clercq P, Geerts A, Van Vlierberghe H, Verhelst X. The utility of biomarkers in prognosis assessment of patients with acute liver failure. Hepatol Res 2021;51:750-7. [PMID: 34076937 DOI: 10.1111/hepr.13668] [Reference Citation Analysis]
325 Wan P, Xia Q, Zhang JJ, Li QG, Xu N, Zhang M, Chen XS, Han LZ. Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience. J Cancer Res Clin Oncol 2014;140:341-8. [PMID: 24374832 DOI: 10.1007/s00432-013-1576-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
326 Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol 2018;16:955-64. [PMID: 29175528 DOI: 10.1016/j.cgh.2017.11.037] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
327 Grąt M, Stypułkowski J, Patkowski W, Bik E, Krasnodębski M, Wronka KM, Lewandowski Z, Wasilewicz M, Grąt K, Masior Ł, Ligocka J, Krawczyk M. Limitations of predicting microvascular invasion in patients with hepatocellular cancer prior to liver transplantation. Sci Rep 2017;7:39881. [PMID: 28057916 DOI: 10.1038/srep39881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
328 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
329 Toniutto P, Bitetto D, Fornasiere E, Fumolo E. Challenges and future developments in liver transplantation. Minerva Gastroenterol Dietol 2019;65:136-52. [PMID: 30303340 DOI: 10.23736/S1121-421X.18.02529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
330 Kutlu OC, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer. 2017;123:1817-1827. [PMID: 28085184 DOI: 10.1002/cncr.30531] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
331 Yang K, Lee T, Choi B, Park Y, Ryu J, Joo D, Chu C. Development and Applicability of the A-P 200 Criteria for Liver Transplantation for Hepatocellular Carcinoma. Transplantation Proceedings 2016;48:3317-22. [DOI: 10.1016/j.transproceed.2016.08.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
332 de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol. 2015;21:11185-11198. [PMID: 26494973 DOI: 10.3748/wjg.v21.i39.11185] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 47] [Article Influence: 13.2] [Reference Citation Analysis]
333 Elshamy M, Aucejo F, Menon KV, Eghtesad B. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. World J Hepatol 2016;8:874-80. [PMID: 27478537 DOI: 10.4254/wjh.v8.i21.874] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
334 Grąt M, Krawczyk M, Stypułkowski J, Morawski M, Krasnodębski M, Wasilewicz M, Lewandowski Z, Grąt K, Patkowski W, Zieniewicz K. Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:4556-65. [PMID: 31520204 DOI: 10.1245/s10434-019-07811-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
335 Morgul MH, Felgendreff P, Kienlein A, Gauger U, Semmling K, Hau HM, Tautenhahn HM, Bartels M. Milan criteria in the MELD era-is it justifiable to extend the limits for orthotopic liver transplantation?World J Surg Oncol. 2020;18:158. [PMID: 32635931 DOI: 10.1186/s12957-020-01932-6] [Reference Citation Analysis]
336 Mohkam K, Rayar M, Adam JP, Muscari F, Rode A, Merle P, Pradat P, Bauler S, Delfour I, Chiche L, Ducerf C, Boudjema K, Lesurtel M, Laurent C, Mabrut JY. Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT). BMC Cancer 2018;18:844. [PMID: 30139340 DOI: 10.1186/s12885-018-4667-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
337 Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology 2017;284:877-86. [PMID: 28453431 DOI: 10.1148/radiol.2017161413] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 17.3] [Reference Citation Analysis]
338 Boteon Y, Flores Carvalho MA, Panconesi R, Muiesan P, Schlegel A. Preventing Tumour Recurrence after Liver Transplantation: The Role of Machine Perfusion. Int J Mol Sci 2020;21:E5791. [PMID: 32806712 DOI: 10.3390/ijms21165791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
339 Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017;3:493-500. [PMID: 27838698 DOI: 10.1001/jamaoncol.2016.5116] [Cited by in Crossref: 111] [Cited by in F6Publishing: 91] [Article Influence: 27.8] [Reference Citation Analysis]
340 Piñero F, Boin I, Chagas A, Quiñonez E, Marciano S, Vilatobá M, Santos L, Anders M, Hoyos Duque S, Soares Lima A, Menendez J, Padilla M, Poniachik J, Zapata R, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, Mendizabal M, Hurtado Gomez S, Stucchi R, Maccali C, Vergara Sandoval R, Bermudez C, McCormack L, Varón A, Gadano A, Mattera J, Rubinstein F, Carrilho F, Silva M. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence. Liver Transpl 2020;26:640-50. [PMID: 32133773 DOI: 10.1002/lt.25744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
341 Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK. Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 2021;5:zrab005. [PMID: 33839747 DOI: 10.1093/bjsopen/zrab005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866-73. [PMID: 30615906 DOI: 10.1016/j.jhep.2018.12.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
343 Xu JH, Chang WH, Fu HW, Yuan T, Chen P. The mRNA, miRNA and lncRNA networks in hepatocellular carcinoma: An integrative transcriptomic analysis from Gene Expression Omnibus. Mol Med Rep 2018;17:6472-82. [PMID: 29512731 DOI: 10.3892/mmr.2018.8694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
344 Chen D, Liu S, Chen S, Wang Z, Wu Z, Ma K, Fan J, Peng Z. Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation. Int J Clin Oncol 2016;21:1111-9. [PMID: 27368337 DOI: 10.1007/s10147-016-1001-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
345 Lai Q, Vitale A. Transplantation for hepatocellular cancer: pushing to the limits? Transl Gastroenterol Hepatol 2018;3:61. [PMID: 30363754 DOI: 10.21037/tgh.2018.09.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
346 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
347 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol. 2016;22:232-252. [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
348 Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.Ann Surg. 2020;272:855-862. [PMID: 32889867 DOI: 10.1097/SLA.0000000000004280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
349 Piñero F, Carrihlo FJ, Silva MO. Predictive models for recurrence risk of hepatocellular carcinoma after liver transplantation: Still an unmet need. Liver Int 2017;37:648-50. [PMID: 28453922 DOI: 10.1111/liv.13417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
350 Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, Sánchez-Frías M, García-Jurado G, Montero JL, Ciria R, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. Cancers (Basel) 2021;13:2476. [PMID: 34069569 DOI: 10.3390/cancers13102476] [Reference Citation Analysis]
351 El-Domiaty N, Saliba F, Vibert E, Karam V, Sobesky R, Ibrahim W, Pittau G, Ciacio O, Salloum C, Amer K, Saeed MA, Shawky JA, Sa Cunha A, Rosmorduc O, Cherqui D, Adam R, Samuel D. Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. Transplantation 2021;105:1778-90. [PMID: 32890134 DOI: 10.1097/TP.0000000000003434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Li C, Wen TF, Yan LN, Li B, Yang JY, Xu MQ, Wang WT, Wei YG. Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation. PLoS One 2013;8:e72235. [PMID: 23991069 DOI: 10.1371/journal.pone.0072235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
353 Artzner T, Michard B, Besch C, Levesque E, Faitot F. Liver transplantation for critically ill cirrhotic patients: Overview and pragmatic proposals. World J Gastroenterol 2018;24:5203-14. [PMID: 30581269 DOI: 10.3748/wjg.v24.i46.5203] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
354 Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64. [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
355 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
356 Guerrero-Misas M, Rodríguez-Perálvarez M, De la Mata M. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol 2015;7:649-61. [PMID: 25866602 DOI: 10.4254/wjh.v7.i4.649] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
357 Tabone M, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol 2020;11:84-90. [PMID: 32175109 DOI: 10.21037/jgo.2019.06.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
358 Lai Q, Inostroza M, Rico Juri JM, Goffette P, Lerut J. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford) 2015;17:1085-95. [PMID: 26373980 DOI: 10.1111/hpb.12486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
359 Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, Boudjema K, Bouattour M, Crehange G, Dauvois B, Decaens T, Dewaele F, Farges O, Guiu B, Hollebecque A, Merle P, Selves J, Aparicio T, Ruiz I, Bouché O; Thésaurus National de Cancérologie Digestive (TNCD)., Société Nationale Française de Gastroentérologie (SNFGE)., Fédération Francophone de Cancérologie Digestive (FFCD)., Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR)., Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER)., Société Française de Chirurgie Digestive (SFCD)., Société Française d’Endoscopie Digestive (SFED)., Société Française de Radiothérapie Oncologique (SFRO)., Association Française pour l’Etude du Foie (AFEF). Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). Clin Res Hepatol Gastroenterol 2021;45:101590. [PMID: 33780876 DOI: 10.1016/j.clinre.2020.101590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
361 Schoenberg MB, Anger HJW, Bucher JN, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visc Med 2020;36:506-15. [PMID: 33447607 DOI: 10.1159/000506752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
362 Zhang Y, Shu Z, Ye Q, Chen J, Zhong J, Jiang H, Wu C, Yu T, Pang P, Ma T, Lin C. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Multi-Parametric MRI Radiomics. Front Oncol 2021;11:633596. [PMID: 33747956 DOI: 10.3389/fonc.2021.633596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014;20:1285. [PMID: 25155484 DOI: 10.1002/lt.23982] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
364 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
365 Ruiz I, Féray C. [Current management of hepatocellular carcinoma]. Cancer Radiother 2015;19:410-5. [PMID: 26337474 DOI: 10.1016/j.canrad.2015.05.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
366 Ling S, Feng T, Zhan Q, Duan X, Jiang G, Shen T, Shan Q, Xu S, Ye Q, Liu P, Cen B, Zheng S, Xu X. Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria. Ann Transl Med 2020;8:80. [PMID: 32175373 DOI: 10.21037/atm.2020.01.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
367 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017;23:3195-204. [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
368 Detry O, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. World J Gastroenterol. 2015;21:3049-3054. [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
369 Zhang Y, Zhang JX, Huang LL, He LJ, Liao YJ, Lai YR, Deng HX, Tian XP, Kung HF, Xie D, Zhu SL. Low expression of BARX2 in human primary hepatocellular carcinoma correlates with metastasis and predicts poor prognosis. Hepatol Res 2015;45:228-37. [PMID: 24716715 DOI: 10.1111/hepr.12340] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
370 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 671] [Article Influence: 156.2] [Reference Citation Analysis]
371 Zamora-Valdes D, Taner T, Nagorney DM. Surgical Treatment of Hepatocellular Carcinoma. Cancer Control 2017;24:1073274817729258. [PMID: 28975836 DOI: 10.1177/1073274817729258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
372 Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899-903. [PMID: 23769067 DOI: 10.1016/j.transproceed.2012.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
373 Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma: An Aggressive Subtype of Hepatocellular Carcinoma. American Journal of Surgical Pathology 2019;43:943-8. [DOI: 10.1097/pas.0000000000001289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 5.5] [Reference Citation Analysis]
374 Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A, Castaing D, Rosmorduc O, Samuel D, Adam R, Cherqui D. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg 2020;272:820-6. [PMID: 32833755 DOI: 10.1097/SLA.0000000000004259] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]